Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2026Annals of HematologyOpen Access

Successful use of ruxolitinib in steroid-refractory chronic GvHD affecting central nervous system: a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

EKEwa Karakulska-PrystupiukBZBeata Zakrzewska-PniewskaATAgnieszka Tomaszewska

Discussion

Loading...

Member takes

Overview

Case report demonstrates ruxolitinib improving neurological symptoms in a woman with CNS-cGvHD, suggesting new treatment possibilities.

Key Points

  • This case report aims to explore ruxolitinib as a treatment for steroid-refractory chronic GvHD affecting the central nervous system.
  • Case study of a 50-year-old woman with steroid-refractory CNS-cGvHD post-allo-HSCT
  • Ruxolitinib initiated at 10 mg/day, increased to 20 mg/day, with prednisone tapering
  • Followed patient for 12 months assessing clinical and radiological improvements
  • Significant clinical recovery and improvement in neurological function after 12 months of ruxolitinib treatment
  • Marked regression of CNS lesions observed on brain MRI
  • Suggests potential benefit of JAK inhibition in treating CNS manifestations of cGvHD

Cite This Study

Karakulska-Prystupiuk et al. (2026) studied this question.

synapsesocial.com/papers/6a0171983a9f334c28271bdchttps://doi.org/10.1007/s00277-026-07064-3
View Full Paper
Ask AI
Bookmark
Share